Trials / Completed
CompletedNCT00959933
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions
A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Non-Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.) | |
| DRUG | Rebetol 200 Capsules (Schering Corporation, U.S.A.) |
Timeline
- Start date
- 2001-04-01
- Primary completion
- 2001-05-01
- Completion
- 2001-05-01
- First posted
- 2009-08-17
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00959933. Inclusion in this directory is not an endorsement.